The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Mutant huntingtin is present in neuronal grafts in huntington disease patients
Abstract
Objective Huntington disease (HD) is caused by a genetically encoded pathological protein (mutant huntingtin [mHtt]), which is thought to exert its effects in a cell-autonomous manner. Here, we tested the hypothesis that mHtt is capable of spreading within cerebral tissue by examining genetically unrelated fetal neural allografts within the brains of patients with advancing HD. Methods The presence of mHtt aggregates within the grafted tissue was confirmed using 3 different types of microscopy (bright-field, fluorescence, and electron), 2 additional techniques consisting of Western immunoblotting and infrared spectroscopy, and 4 distinct antibodies targeting different epitopes of mHtt aggregates. Results We describe the presence of mHtt aggregates within intracerebral allografts of striatal tissue in 3 HD patients who received their transplants approximately 1 decade earlier and then died secondary to the progression of their disease. The mHtt(+) aggregates were observed in the extracellular matrix of the transplanted tissue, whereas in the host brain they were seen in neurons, neuropil, extracellular matrix, and blood vessels. Interpretation This is the first demonstration of the presence of mHtt in genetically normal and unrelated allografted neural tissue transplanted into the brain of affected HD patients. These observations raise questions on protein spread in monogenic neurodegenerative disorders of the central nervous system characterized by the formation of mutant pro…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, mutant huntingtin aggregates accumulate in brain endothelial cells, perivascular macrophages, SMCs, and vascular basal lamina in HD (155), and in genetically unrelated neural allografts within the brains of patients with advanced HD (114), suggesting that cerebral vasculature may contribute spreading of mutant huntingtin.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [114]
Citations
Cites
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,816
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Self-citationInclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Steffan, J. S., Kazantsev, A. G., Spasić-Bošković, O., Greenwald, M., Zhu, Y., Goehler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,057
Trans-Synaptic Spread of Tau Pathology In Vivo
Liu, L., Drouet, V., Wu, J., Witter, M. P., Small, S. A., Clelland, C. L. T., & Duff, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031302 · Cited by 994
Cited by
Sorted by citations
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 568
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic StrategiesPreprint
Jiménez-Sánchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 534
Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0238-6 · Cited by 450
Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration
Goedert, M., Masuda-Suzukake, M., & Falcon, B. (2017) · Brain · doi:10.1093/brain/aww230 · Cited by 323
Propagation of Protein Aggregation in Neurodegenerative Diseases
Vaquer‐Alicea, J., & Diamond, M. I. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045049 · Cited by 316
Drouin‐Ouellet, J., Sawiak, S. J., Cisbani, G., Lagacé, M., Kuan, W., Saint‐Pierre, M., Dury, R. J., Alata, W., St‐Amour, I., Mason, S. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24406 · Cited by 288
Self-citationThe choreography of neuroinflammation in Huntington's disease
Crotti, A., & Glass, C. K. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.007 · Cited by 276
New approaches for brain repair-from rescue to reprogramming
Barker, R. A., Götz, M., & Parmar, M. (2018) · Nature · doi:10.1038/s41586-018-0087-1 · Cited by 214
Self-citationClinical Features of Huntington’s Disease
Ghosh, R., & Tabrizi, S. J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-71779-1_1 · Cited by 207
Human-to-mouse prion-like propagation of mutant huntingtin protein
Jeon, I., Cicchetti, F., Cisbani, G., Lee, S., Li, E., Bae, J., Lee, N., Li, L., Im, W., Kim, M., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1582-9 · Cited by 197
Self-citationBourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bézard, E., Dehay, B., & Tsarbopoulos, A. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 202
Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support
Marsh, S. E., & Blurton-Jones, M. M. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.006 · Cited by 183
Alpha-synuclein spreading in Parkinson’s disease
Recasens, A., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00159 · Cited by 192
Axonal transport and secretion of fibrillar forms of α-synuclein, Aβ42 peptide and HTTExon 1
Brahic, M., Bousset, L., Bieri, G., Melki, R., & Gitler, A. D. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1538-0 · Cited by 169
Therapeutic Advances for Huntington’s Disease
Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 170
Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain
Pearce, M. M. P., Spartz, E. J., Hong, W., Luo, L., & Kopito, R. R. (2015) · Nature Communications · doi:10.1038/ncomms7768 · Cited by 159
Vaquer‐Alicea, J., Diamond, M. I., & Joachimiak, Ł. A. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02301-7 · Cited by 139
The role of tau in the pathological process and clinical expression of Huntington’s disease
Vuono, R., Winder‐Rhodes, S., de Silva, R., Cisbani, G., Drouin‐Ouellet, J., REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini, M. G., Cicchetti, F., & Barker, R. A. (2015) · Brain · doi:10.1093/brain/awv107 · Cited by 139
Self-citationIntercellular Spread of Protein Aggregates in Neurodegenerative Disease
Davis, A. A., Leyns, C. E. G., & Holtzman, D. M. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062636 · Cited by 131
The prion model for progression and diversity of neurodegenerative diseases
Stopschinski, B. E., & Diamond, M. I. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30037-6 · Cited by 133
Regulated cell death: discovery, features and implications for neurodegenerative diseases
Cui, J., Zhao, S., Li, Y., Zhang, D., Wang, B., Xie, J., & Wang, J. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00799-8 · Cited by 130
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Zhang, X., Abels, E. R., Redzic, J. S., Margulis, J., Finkbeiner, S. M., & Breakefield, X. O. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0350-7 · Cited by 101
Reidling, J. C., Relaño-Ginés, A., Holley, S. M., Ochaba, J., Moore, C., Fury, B., Lau, A., Tran, A. H., Yeung, S. Y., Salamati, D., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.11.005 · Cited by 99
Berberine: A Promising Treatment for Neurodegenerative Diseases
Cheng, Z., Kang, C., Che, S., Su, J., Sun, Q., Ge, T., Guo, Y. C., Lv, J., Sun, Z., Yang, W., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.845591 · Cited by 98
L’Episcopo, F., Drouin‐Ouellet, J., Tirolo, C., Pulvirenti, A., Giugno, R., Testa, N., Caniglia, S., Serapide, M. F., Cisbani, G., Barker, R., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.104 · Cited by 94
Self-citationMutant Huntingtin Is Secreted via a Late Endosomal/Lysosomal Unconventional Secretory Pathway
Trajkovic, K., Jeong, H., & Krainc, D. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0118-17.2017 · Cited by 85
DeGuire, S. M., Ruggeri, F. S., Fares, M.-B., Chiki, A., Cendrowska, U., Dietler, G., & Lashuel, H. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004621 · Cited by 80
Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion
Sharma, M., & Subramaniam, S. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201807068 · Cited by 76
Emerging Roles of Exosomes in Huntington’s Disease
Ananbeh, H., Vodička, P., & Skalníková, H. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084085 · Cited by 84
Ubiquitin, Autophagy and Neurodegenerative Diseases
Watanabe, Y., Taguchi, K., & Tanaka, M. (2020) · Cells · doi:10.3390/cells9092022 · Cited by 86
Is Huntington's disease a tauopathy?
Gratuze, M., Cisbani, G., Cicchetti, F., & Planel, E. (2016) · Brain · doi:10.1093/brain/aww021 · Cited by 81
Self-citationFan, D., Liu, L., Wu, Z., & Cao, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180419141613 · Cited by 80
Dopamine and Huntington’s disease
Schwab, L. C., Garas, S. N., Drouin‐Ouellet, J., Mason, S., Stott, S., & Barker, R. A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1025383 · Cited by 79
Self-citationDeng, J., Koutras, C., Donnelier, J., Alshehri, M., Fotouhi, M., Girard, M., Casha, S., McPherson, P. S., Robbins, S. M., & Braun, J. E. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-01115-6 · Cited by 70
Reactive astrocytes promote proteostasis in Huntington’s disease through the JAK2-STAT3 pathway
Abjean, L., Haim, L. B., Riquelme‐Perez, M., Gipchtein, P., Derbois, C., Palomares, M.-A., Petit, F., Hérard, A., Gaillard, M., Guillermier, M., et al. (2022) · Brain · doi:10.1093/brain/awac068 · Cited by 79
Ex vivo gene therapy for the treatment of neurological disorders
Gowing, G., Svendsen, S. P., & Svendsen, C. N. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.11.003 · Cited by 74
Katt, M. E., Mayo, L. N., Ellis, S., Mahairaki, V., Rothstein, J. D., Cheng, L., & Searson, P. C. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0139-4 · Cited by 69
Therapeutic advances in Huntington's Disease
Shannon, K. M., & Fraint, A. (2015) · Movement Disorders · doi:10.1002/mds.26331 · Cited by 72
A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study
Hashizume, A., Katsuno, M., Suzuki, K., Banno, H., Suga, N., Mano, T., Araki, A., Hijikata, Y., Grunseich, C., Kokkinis, A. D., et al. (2015) · Neuromuscular Disorders · doi:10.1016/j.nmd.2015.03.008 · Cited by 71
Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease
Caron, N. S., Banos, R., Yanick, C., Aly, A. E., Byrne, L. M., Smith, E. D., Xie, Y., Smith, S. E. P., Potluri, N., Findlay Black, H., et al. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1865-20.2020 · Cited by 66
Cisbani, G., Maxan, A., Kordower, J. H., Planel, E., Freeman, T. B., & Cicchetti, F. (2017) · Brain · doi:10.1093/brain/awx255 · Cited by 67
Self-citationExosomes: Innocent Bystanders or Critical Culprits in Neurodegenerative Diseases
Beatriz, M., Vilaça, R., & Lopes, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.635104 · Cited by 67
Molecular mechanisms of proteinopathies across neurodegenerative disease: a review
Marsh, A. (2019) · Neurological Research and Practice · doi:10.1186/s42466-019-0039-8 · Cited by 64
Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington’s disease
Gratuze, M., Noël, A., Julien, C., Cisbani, G., Milot-Rousseau, P., Morin, F., Dickler, M., Goupil, C., Bezeau, F., Poitras, I., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu456 · Cited by 65
Self-citationSystemic manifestation and contribution of peripheral tissues to Huntington’s disease pathogenesis
Chuang, C.-L., & Demontis, F. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101358 · Cited by 66
Masnata, M., Sciacca, G., Maxan, A., Bousset, L., Denis, H. L., Lauruol, F., David, L. S., Saint‐Pierre, M., Kordower, J. H., Melki, R., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01973-6 · Cited by 64
Self-citationResearch progress on the role of extracellular vesicles in neurodegenerative diseases
Li, Z., Wang, X., Wang, X., Yi, X., Wong, Y. K., Wu, J., Xie, F., Hu, D., Wang, Q., Wang, J., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00375-9 · Cited by 67
Nonhuman Primate Models of Neurodegenerative Disorders
Emborg, M. E. (2017) · ILAR Journal · doi:10.1093/ilar/ilx021 · Cited by 64
Primary cilia and autophagic dysfunction in Huntington’s disease
Kaliszewski, M., Knott, A. B., & Bossy-Wetzel, E. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.80 · Cited by 55
The Cell Biology of Tau Secretion
Merezhko, M., Uronen, R., & Huttunen, H. J. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.569818 · Cited by 65
Huntington’s disease: the coming of age
Pandey, M., & Rajamma, U. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0957-1 · Cited by 56
Huntington’s disease cerebrospinal fluid seeds aggregation of mutant huntingtin
Tan, Z., Dai, W., van Erp, T. G. M., Overman, J., Demuro, A., Digman, M. A., Hatami, A., Albay, R., Sontag, E. M., Potkin, K. T., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.81 · Cited by 57
Prion-Like Characteristics of Polyglutamine-Containing ProteinsPreprint
Pearce, M. M. P., & Kopito, R. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024257 · Cited by 53
Tissue specific microenvironments: a key tool for tissue engineering and regenerative medicine
Sachs, P. C., Mollica, P. A., & Bruno, R. D. (2017) · Journal of Biological Engineering · doi:10.1186/s13036-017-0077-0 · Cited by 51
Andrade, C., Beato, J. N., Monteiro, A., da Costa, A. G., Penas, S. C., Guimarães, J., Falcão‐Reis, F., & Garrett, C. (2016) · Movement Disorders · doi:10.1002/mds.26486 · Cited by 51
Gharaibeh, A., Culver, R., Stewart, A. N., Srinageshwar, B., Spelde, K., Frollo, L., Kolli, N., Story, D. T., Paladugu, L., Anwar, S., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00628 · Cited by 50
André, E. M., Passirani, C., Seijo, B., Sánchez, A., & Montero‐Menei, C. N. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.008 · Cited by 50
Lobo, D. D., Nobre, R. J., Miranda, C. O., Pereira, D., Castelhano, J., Sereno, J., Koeppen, A. H., Castelo-Branco, M. S., & de Almeida, L. P. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00955-0 · Cited by 45
Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington’s Disease
D’Egidio, F., Castelli, V., Cimini, A., & d’Angelo, M. (2023) · Antioxidants · doi:10.3390/antiox12030571 · Cited by 42
Kerkis, I., Haddad, M. S., Valverde, C. W., & Glosman, S. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0248-1 · Cited by 43
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic
Miniarikova, J., Evers, M. M., & Konstantinova, P. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.002 · Cited by 43
van Roon‐Mom, W., Roos, R. A. C., & de Bot, S. T. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0720 · Cited by 41
Developing Stem Cell Therapies for Juvenile and Adult-Onset Huntington's Disease
Fink, K. D., Deng, P., Torrest, A., Stewart, H., Pollock, K., Gruenloh, W., Annett, G., Tempkin, T., Wheelock, V., & Nolta, J. A. (2015) · Regenerative Medicine · doi:10.2217/rme.15.25 · Cited by 41
Karystianis, G., Sheppard, T., Dixon, W. G., & Nenadić, G. (2015) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-016-0255-x · Cited by 41
Selective Neuronal Death in Neurodegenerative Diseases: The Ongoing Mystery.
Subramaniam, S. (2019) · Europe PMC (PubMed Central) · Cited by 40
The prion-like phenomenon in Alzheimer’s disease: Evidence of pathology transmission in humans
Gomez‐Gutierrez, R., & Morales, R. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009004 · Cited by 39
Cicchetti, F., & Barker, R. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00139 · Cited by 39
Self-citationMasnata, M., & Cicchetti, F. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00647 · Cited by 39
Self-citationCell therapy in Huntington's disease: Taking stock of past studies to move the field forward
Bachoud‐Lévi, A., Massart, R., & Rosser, A. (2020) · Stem Cells · doi:10.1002/stem.3300 · Cited by 41
Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease
Miguez, A., Gomis, C., Vila, C., Tortajada, M., Fernández‐García, S., Bombau, G., Galofré, M., García-Bravo, M., Sanders, P., Fernández-Medina, H., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04882-w · Cited by 38
Huntington's disease: Current and future therapeutic prospects
Kieburtz, K. D., Reilmann, R., & Olanow, C. W. (2018) · Movement Disorders · doi:10.1002/mds.27363 · Cited by 38
Jacquet, A. D. R., Denis, H. L., Cicchetti, F., & Alpaugh, M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00999-7 · Cited by 36
Self-citationNew Directions in Therapeutics for Huntington Disease
Potkin, K. T., & Potkin, S. G. (2018) · Future Neurology · doi:10.2217/fnl-2017-0035 · Cited by 36
The Role of Extracellular Matrix Components in the Spreading of Pathological Protein Aggregates
Moretto, E., Stuart, S., Surana, S., Vargas, J. N. S., & Schiavo, G. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.844211 · Cited by 32
Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?
Salado-Manzano, C., Perpiñá, U., Straccia, M., Molina-Ruiz, F. J., Cozzi, E., Rosser, A., & Canals, J. M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00250 · Cited by 34
Cell Encapsulation and 3D Bioprinting for Therapeutic Cell Transplantation
Samadi, A., Moammeri, A., Pourmadadi, M., Abbasi, P., Hosseinpour, Z., Farokh, A., Shamsabadipour, A., Heydari, M., & Mohammadi, M. R. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01183 · Cited by 36
“Prion-like” seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders
Zampar, S., Gregorio, S. E. D., Grimmer, G., Watts, J. C., & Ingelsson, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1436262 · Cited by 39
Unconventional Secretion and Intercellular Transfer of Mutant Huntingtin
Tang, B. L. (2018) · Cells · doi:10.3390/cells7060059 · Cited by 34
Vieweg, S., Mahul‐Mellier, A., Ruggeri, F. S., Riguet, N., DeGuire, S. M., Chiki, A., Cendrowska, U., Dietler, G., & Lashuel, H. A. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167222 · Cited by 34
Rhes protein transits from neuron to neuron and facilitates mutant huntingtin spreading in the brain
Ramírez-Jarquín, U. N., Sharma, M., Shahani, N., Li, Y., Boregowda, S. V., & Subramaniam, S. (2022) · Science Advances · doi:10.1126/sciadv.abm3877 · Cited by 33
Rieux, M., Alpaugh, M., Sciacca, G., Saint‐Pierre, M., Masnata, M., Denis, H. L., Lévesque, S. A., Herrmann, F., Bazenet, C. E., Garneau, A. P., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0787-4 · Cited by 32
Self-citationSzlachcic, W. J., Wiatr, K., Trzeciak, M., Figlerowicz, M., & Figiel, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00253 · Cited by 31
From open to large-scale randomized cell transplantation trials in Huntington's disease
Bachoud‐Lévi, A. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.12.011 · Cited by 29
Antibody-based therapies for Huntington’s disease: current status and future directions
Denis, H. L., David, L. S., & Cicchetti, F. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104569 · Cited by 33
Self-citationOutcome of cell suspension allografts in a patient with Huntington's disease
Maxan, A., Mason, S., Saint‐Pierre, M., Smith, E., Ho, A. K., Harrower, T., Watts, C., Tai, Y., Pavese, N., Savage, J. C., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25354 · Cited by 27
Self-citationPark, H. J., Jeon, J., Choi, J., Kim, J. Y., Kim, H. S., Huh, J. Y., Goldman, S. A., & Song, J. (2021) · Cell Proliferation · doi:10.1111/cpr.13082 · Cited by 28
Molecular mechanisms of heterogeneous oligomerization of huntingtin proteins
Bonfanti, S., Lionetti, M. C., Fumagalli, M. R., Chirasani, V. R., Tiana, G., Dokholyan, N. V., Zapperi, S., & Porta, C. A. M. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-44151-0 · Cited by 27
Visualization of prion-like transfer in Huntington's disease models
Jansen, A. H. P., Batenburg, K. L., Pecho‐Vrieseling, E., & Reits, E. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.12.015 · Cited by 26
Passive immunization against phosphorylated tau improves features of Huntington's disease pathology
Alpaugh, M., Masnata, M., de Rus Jacquet, A., Lepinay, E., Denis, H. L., Saint-Pierre, M., Davies, P., Planel, E., & Cicchetti, F. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.020 · Cited by 25
Self-citationCell-to-cell Transmission of Polyglutamine Aggregates inC. elegans
Kim, D., Cho, K.-W., Ahn, W. J., Pérez-Acuña, D., Jeong, H., Lee, H.-J., & Lee, S. (2017) · Experimental Neurobiology · doi:10.5607/en.2017.26.6.321 · Cited by 27
Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington’s disease
Liu, C.-F., Laurent Younes, B., Tong, X. J., Hinkle, J. T., Wang, M., Phatak, S., Xu, X., Bu, X., Looi, V., Bang, J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad214 · Cited by 23
Targeting Tau to Treat Clinical Features of Huntington's Disease
Masnata, M., Salem, S., Jacquet, A. D. R., Anwer, M., & Cicchetti, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580732 · Cited by 25
Self-citationLiu, L., Huang, J., Han, C., Zhang, G., Xu, X., Shen, Y., Li, J., Jiang, H., Lin, Z., Xiong, N., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9601-8 · Cited by 23
Hunting for the cause: Evidence for prion-like mechanisms in Huntington’s disease
Donnelly, K. M., Coleman, C. M., Fuller, M. L., Reed, V. L., Smerina, D., Tomlinson, D. S., & Pearce, M. M. P. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.946822 · Cited by 20
Mutant huntingtin protein expression and blood–spinal cord barrier dysfunction in huntington disease
Sciacca, G., & Cicchetti, F. (2017) · Annals of Neurology · doi:10.1002/ana.25107 · Cited by 21
Self-citationWang, X., Shuai, W., Yang, P., Liu, Y., Zhang, Y., & Wang, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102584 · Cited by 19
Metadata
- Authors
- Cicchetti, F., Lacroix, S., Cisbani, G., Vallières, N., Saint‐Pierre, M., St‐Amour, I., Tolouei, R., Skepper, J. N., Hauser, R. A., Mantovani, D., Barker, R. A., & Freeman, T. B.
- Affiliations
- Centre hospitalier universitaire de Québec (CA)
- Hôpital Saint-François d'Assise (CA)
- University of Cambridge (GB)
- University of South Florida (US)
- Corresponding author
- Cicchetti, Francesca
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2014-06-06
- Volume
- 76
- Issue
- 1
- Pages
- 31-42
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2148853271
- Cited by
- 193
- References
- 49
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 10 · 2023: 15 · 2022: 18 · 2021: 18 · 2020: 21 · 2019: 12 · 2018: 23 · 2017: 21 · 2016: 12 · 2015: 19 · 2014: 8
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- International Organization of Glutaric Acidemia (IOGA)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- mutant huntingtin, protein aggregation, striatal transplantation, extracellular matrix
- MeSH terms
- Huntingtin Protein, Adult, Clinical Trials as Topic, Humans, Huntington Disease, Middle Aged, Mutation, Nerve Tissue Proteins, Fetal Tissue Transplantation, Brain Tissue Transplantation, Neostriatum, Allografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
